• 1. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Imidazoles Substituted imidazoles

Dacarbazine-D6 (CAS No. 1185241-28-4): A Comprehensive Guide to Its Properties and Applications

Dacarbazine-D6 is a deuterated analog of the well-known chemotherapeutic agent Dacarbazine. With the CAS number 1185241-28-4, this compound has gained significant attention in pharmaceutical research, particularly in the fields of oncology and drug metabolism studies. The incorporation of six deuterium atoms (D6) enhances its utility as an internal standard in mass spectrometry, making it invaluable for quantitative analysis.

The molecular structure of Dacarbazine-D6 closely resembles its non-deuterated counterpart, but the presence of deuterium atoms provides distinct advantages in analytical applications. Researchers often utilize this compound in LC-MS (Liquid Chromatography-Mass Spectrometry) and GC-MS (Gas Chromatography-Mass Spectrometry) workflows to improve accuracy and reproducibility. The growing demand for deuterated compounds in drug development has positioned Dacarbazine-D6 as a critical tool in modern laboratories.

One of the most common questions about Dacarbazine-D6 is: "How does deuterium labeling affect drug metabolism studies?" The answer lies in the kinetic isotope effect, where deuterium-carbon bonds are more stable than hydrogen-carbon bonds. This property allows researchers to track drug pathways more effectively, reducing background noise in analytical data. As a result, Dacarbazine-D6 is frequently used in pharmacokinetic studies and bioavailability research.

In recent years, the application of Dacarbazine-D6 has expanded beyond traditional cancer research. With the rise of personalized medicine and precision oncology, this compound plays a pivotal role in developing targeted therapies. Scientists are also exploring its potential in combination therapies, where deuterated compounds can enhance drug efficacy while minimizing side effects.

The market for deuterated pharmaceuticals is projected to grow significantly, driven by advancements in analytical chemistry and drug discovery. As a high-purity reference material, Dacarbazine-D6 (CAS 1185241-28-4) meets the stringent requirements of regulatory agencies, making it a preferred choice for quality control in pharmaceutical manufacturing.

Another trending topic in the scientific community is the use of stable isotope-labeled compounds in metabolomics. Researchers are leveraging Dacarbazine-D6 to uncover new biomarkers and metabolic pathways, contributing to breakthroughs in disease diagnosis and treatment. Its compatibility with high-resolution mass spectrometers further enhances its utility in cutting-edge research.

For laboratories seeking reliable reference standards, Dacarbazine-D6 offers exceptional stability and consistency. Proper storage conditions—typically at -20°C in a dry environment—ensure long-term usability. When handling this compound, researchers should follow standard laboratory protocols to maintain its integrity for quantitative analysis.

In conclusion, Dacarbazine-D6 (CAS 1185241-28-4) represents a vital resource for modern pharmaceutical and clinical research. Its applications span from cancer drug development to metabolic profiling, aligning with the latest trends in biomedical innovation. As the demand for deuterated compounds continues to rise, this specialized chemical will remain at the forefront of scientific discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)